Abpro Bio Balance Sheet Health
Financial Health criteria checks 6/6
Abpro Bio has a total shareholder equity of ₩122.6B and total debt of ₩15.9B, which brings its debt-to-equity ratio to 12.9%. Its total assets and total liabilities are ₩152.6B and ₩30.1B respectively.
Key information
12.9%
Debt to equity ratio
₩15.86b
Debt
Interest coverage ratio | n/a |
Cash | ₩16.22b |
Equity | ₩122.57b |
Total liabilities | ₩30.05b |
Total assets | ₩152.62b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A195990's short term assets (₩48.0B) exceed its short term liabilities (₩24.1B).
Long Term Liabilities: A195990's short term assets (₩48.0B) exceed its long term liabilities (₩5.9B).
Debt to Equity History and Analysis
Debt Level: A195990 has more cash than its total debt.
Reducing Debt: A195990's debt to equity ratio has reduced from 46.1% to 12.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A195990 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A195990 has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 4.9% each year.